US7749490B2ExpiredUtilityPatentIndex 88
Mutant IL-10
Est. expiryMay 31, 2025(expired)· nominal 20-yr term from priority
A61P 7/00A61P 43/00A61P 9/10A61P 37/02A61P 5/14A61P 5/38A61P 37/06A61P 9/04A61P 9/08A61P 3/06A61P 9/00A61P 7/06A61P 7/08A61P 39/02A61P 3/10A61P 33/06A61P 33/10A61P 25/00A61P 35/00A61P 31/18A61P 31/08A61P 25/14A61P 31/04A61P 31/12A61P 27/02A61P 25/02A61P 31/22A61P 33/02A61P 29/00A61P 25/16A61P 25/20A61P 25/04A61P 3/00A61P 25/08A61P 31/06A61P 25/06A61P 25/28A61P 13/02A61P 1/04A61P 1/02A61P 15/00A61P 11/06A61P 1/08A61P 1/16A61P 11/00A61P 13/12A61P 21/02C07K 14/5428A61P 19/00A61P 19/02A61P 21/04A61P 19/10A61P 17/02A61K 38/2066A61P 17/06
88
PatentIndex Score
34
Cited by
3
References
4
Claims
Abstract
IL-10 sequence variants are disclosed that retain the therapeutically desirable anti-inflammatory properties of wild-type IL-10 but do not retain the hemoatopoeitic cell regulatory and cell proliferative activities. The mutant IL-10 polypeptides of the invention are used in methods of treating diseases involving inflammatory response, including neuropathic pain and other neurological disorders.
Claims
exact text as granted — not AI-modified1. An isolated mutant IL-10 polypeptide, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:3 with a substitution of serine for phenylalanine at position 129 of SEQ ID NO:2 or SEQ ID NO:3.
2. A method of treating neuropathic pain in a subject comprising administering to said subject a therapeutic amount of an IL-10 polypeptide according to claim 1 .
3. An isolated mutant IL-10 polypeptide, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:1.
4. The IL-10 polypeptide of claim 3 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:1.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.